---
title: "\"Abnormal Movement\" TRANSTHERA-B surged 16% in the early stage, recently suggesting the implementation of full circulation for H shares"
description: "TRANSTHERA-B opened down 2.1% this morning but surged 16.5% afterwards, currently trading at 201.2 yuan, with a transaction volume of 529 million yuan. The company's board of directors has approved th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262145738.md"
published_at: "2025-10-22T01:52:11.000Z"
---

# "Abnormal Movement" TRANSTHERA-B surged 16% in the early stage, recently suggesting the implementation of full circulation for H shares

> TRANSTHERA-B opened down 2.1% this morning but surged 16.5% afterwards, currently trading at 201.2 yuan, with a transaction volume of 529 million yuan. The company's board of directors has approved the application to the China Securities Regulatory Commission to convert 44.97 million domestic shares held by 10 shareholders into H shares, accounting for approximately 11.33% of the issued shares. The stock was listed in June and has incurred a loss of 123 million yuan in six months, having previously soared over 50 times within less than three months of listing

TRANSTHERA-B (02617.HK) opened down 2.1% this morning (22nd) but quickly reversed to rise sharply, currently reported at HKD 201.2, up 16.5%, with a transaction volume of HKD 529 million.

The group announced on Monday that the board has considered and approved the submission of an application to the China Securities Regulatory Commission to convert 44.97 million domestic shares held by 10 shareholders into H shares, accounting for approximately 11.33% of the company's currently issued share capital. Upon obtaining all relevant approvals, these domestic shares will be converted into H shares and will qualify for listing and trading on the main board of the Stock Exchange. According to the company's articles of association, there is no need to hold a shareholders' meeting to approve the conversion and listing.

The stock was listed in late June and had not recorded any revenue for the half-year ending in June, with a loss of RMB 123 million, compared to a loss of RMB 160 million in the previous fiscal year. The stock had surged over 50 times within less than three months of listing, with the share price peaking at HKD 679.5 in mid-September, and its market value once exceeding HKD 200 billion, even surpassing pharmaceutical blue chips such as China National Pharmaceutical Group (01177.HK) and Stone Pharmaceutical (01093.HK), before sharply declining

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股異動：藥捷安康-B 漲 16.21%，資金流向活躍，板塊趨勢引發市場關注？ | 藥捷安康-B 漲 16.21%；三生製藥跌 1.44%，成交額達到 1.3 億港幣；信達生物跌 1.01%，成交額達到 1.17 億港幣；康方生物跌 1.52%，成交額達到 70.04 百萬港幣；百濟神州跌 1.14%，市值達到 2799  | [Link](https://longbridge.com/en/news/271050704.md) |
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |
| Mikrobiomik 獲得了用於治療艱難梭菌感染的腸道微生物羣療法的批准 | Mikrobiomik 已在西班牙獲得其口服療法 EUTEGRA (MBK-01) 的批准，用於治療艱難梭菌感染，標誌着其成為首個為此目的處理糞便微生物羣的組織。該療法採用 FSPIM 技術，為傳統抗生素治療提供了一種替代方案。此次批准是在 | [Link](https://longbridge.com/en/news/276345316.md) |
| 美股「黑幕」：10b5-1 計劃漏洞是否合法內幕交易｜藍血工廠 | 美國的 Governance 存在漏洞，ADM 因會計問題被 SEC 調查並罰款 4000 萬美元。CEO 在股價高位時利用 10b5-1 計劃拋售近 2000 萬美元股票，成功避開股價下跌。此類操作並非個案，EBS 公司 CEO 在疫苗汙 | [Link](https://longbridge.com/en/news/275224827.md) |
| 12:30 ETInventHelp 的發明者開發了一種新的健康飲品 (RKH-697) | InventHelp 宣佈開發了一種名為 TRINITY PUNCH 的新型健康飲品，由來自弗吉尼亞州 Courtland 的發明者創作。該飲品旨在提供健康益處，並作為傳統果汁的替代品。它採用全自然配方，適合各個年齡段的消費者，促進放鬆和緩 | [Link](https://longbridge.com/en/news/276362497.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.